IPO ChampIPO Insights
IPO Champ LogoIPO Champ Logo

IPOs

IPO Calendar
GMP Tracker
Subscription Status
Allotment Status
Stock Broker
  • Follow us on Instagram
  • Follow us on Facebook
  • Follow us on Threads
  • Follow us on YouTube
  • Follow us on Telegram
  • Follow us on WhatsApp
HomeIPOSilexion Therapeutics Corp

About

Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Silexion Therapeutics Corp Overview

Ticker, listing venue and issuer profile

TickerSLXN
ExchangeNASDAQ
Statusupcoming
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
CIK Code2022416
CUSIPG1281K148
ISINKYG1281K1489

Offer & Key Dates

Pricing terms and IPO milestones

Price Range--
Offer Price--
Listing Price$1,608.00
Current Price$1.04
Shares Offered--
Shares Outstanding419K
Offer Size--
Market Cap$433.66K
Filing Date--
Priced Date--
Listed DateAug 12, 2026

Live Market Snapshot

Real-time price and trading activity

$1.03-99.94% All time

USD · NASDAQ:NASDAQ:SLXN

Open$1.49
High$1.50
Low$1.02
Volume2,029,721
52W High$80.00
52W Low$1.02
Market Cap$1.10M
Enterprise Value$3.68M

Valuation & Multiples

Key valuation ratios and metrics

P / E--
P / Book1.11
P / Sales--
EV / EBITDA--
EPS-94.56
Revenue / Share (TTM)0
Revenue$0.00
Net Income-$11.91M

Financial Health

Balance sheet strength and liquidity

Total Debt$1.99M
Total Assets$4.60M
Cash$6.02M
Free Cash Flow-$12.02M
Current Ratio1
Quick Ratio1
Debt / Equity6.84
CapEx-$3.00K

Profitability & Returns

Margins and return on capital

Gross Margin--
Operating Margin--
Net Margin--
Return on Equity-897.46%
Return on Assets-200.00%
ROIC-400.00%
EBITDA-$12.72M
Gross Profit-$14.00K

Analyst Estimates

Street consensus and price targets

1Y Target$6.00
Median Target$6.00
Rating (1=Strong Buy)2
EPS Fcst (FQ)-12.9

Risk Metrics

Volatility versus the market

Beta1.04
3Y Beta-0.11
5Y Beta-0.25

Earnings Calendar

Upcoming and recent earnings

Next EarningsAug 18, 2026
Last EarningsMay 18, 2026
EPS Fcst (Next FQ)-21.2
EPS Fcst (FQ)-12.9

Financial Highlights

Historical financial performance

SEC Filings

Official documents from SEC EDGAR

FormFiling DateDocument
EFFECTAug 11, 2026Notice of Effectiveness
S-1/AAug 10, 2026[Amend] General form for registration of securities under the Securities Act of 1933
8-KAug 10, 2026Current Report
S-1Aug 7, 2026General form for registration of securities under the Securities Act of 1933
8-KAug 4, 2026Current Report
8-KAug 3, 2026Current Report
8-KJul 31, 2026Current Report
8-KJul 29, 2026Current Report
8-KJul 21, 2026Current Report
DEFA14AJul 13, 2026Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Company Info

Contact and headquarters details

Websitehttps://silexion.com
HeadquartersIsrael
Founded2008
Employees14
Phone972 2 674 3430
AddressThe Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical CtrJerusalem, 9112001Israel

Leadership

Key executives and officers

IH

Ilan Hadar M.B.A.

Chairman and Chief Executive Officer

MH

Mirit Horenshtein Hadar

Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary

DM

Dr. Mitchell Shirvan M.B.A., Ph.D.

Chief Scientific and Development Officer

Silexion Therapeutics Corp IPO - FAQs

The current price of SLXN is 1.03 USD — it has decreased by −31.00% in the past 24 hours. Watch Silexion Therapeutics Corp stock price performance more closely on the chart.

Quick Facts

Exchange
NASDAQ
Ticker
SLXN
Deal Type
IPO
Offer Size
--
Market Cap
$433.66K
Shares Offered
--

Company Info

Website
https://silexion.com
Headquarters
Israel
Founded
2008
Employees
14
Phone
972 2 674 3430
Address
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical CtrJerusalem, 9112001Israel
IPO Champ LogoIPO Champ Logo

IPO Champ helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO CalendarGMP TrackerSubscription StatusAllotment Status

IPOs

All IPOsLive IPOsUpcoming IPOsClosed IPOsListed IPOs

Resources

NewseBooks

Company

HomeAbout UsPrivacy PolicyTerms of Service

About IPO Champ

IPO Champ is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@ipochamp.com.

Please read all offer documents and risk disclosures carefully before investing. IPO Champ does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Champ. All rights reserved.

Want to stay updated?Subscribe to our newsletter

Silexion Therapeutics Corp

Silexion Therapeutics Corp

SLXNNASDAQ
upcoming

Shares

419K shares

Listing Price

$1,608.00

Probable listing

Aug 12, 2026

Sector

Healthcare